Key Milestone for Tata 1mg
Tata 1mg has reported a significant achievement, turning Ebitda positive across all its core business units in FY26. This marks a pivotal moment for the digital healthcare platform as it continues to expand its services in pharmacy, diagnostics, and specialty care.
Diagnostics Business Growth
The diagnostics segment has notably crossed an annualized revenue run rate of over Rs 600 crore, reflecting a year-on-year growth of over 40%. The segment has also maintained double-digit Ebitda margins, showcasing its profitability.
Expansion of Services
Tata 1mg operates 19 NABL-accredited labs across 70 cities, with its National Reference Lab accredited by the College of American Pathologists (CAP). The company has also expanded its offline retail presence to over 280 stores and plans to increase this to more than 500 stores in the coming year.
Performance Highlights
- The ePharmacy segment achieved breakeven while expanding its scale.
- Express medicine delivery services are now available in 10 cities.
- The Specialty Pharma business grew by approximately 65% in FY26.
- Direct-to-consumer health products surpassed Rs 200 crore in annual revenue and remained profitable.
Future Growth Strategy
Looking ahead, Tata 1mg aims to enhance its offerings by focusing on faster pharmacy deliveries and expanding diagnostics into radiology and specialized testing. The company is also investing in AI-driven personalization to improve customer experiences.
Leadership Insights
Co-founder and CEO Prashant Tandon emphasized that FY26 represents an inflection point for the company, attributing success to a decade of building an integrated healthcare model. He expressed confidence in the company's potential to capture a larger market share in the future.
Technological Investments
Tata 1mg continues to invest in technology as a competitive advantage. Its AI-powered insights platform, Pulse, is utilized by over 75 pharmaceutical companies, reinforcing the company's role in the health intelligence sector.
Conclusion
As Tata 1mg progresses, it remains committed to building a trusted integrated, omnichannel healthcare platform aimed at delivering personalized, predictive, and preventive healthcare solutions.
